Psychiatric Consultants,PC

Franklin, Tennessee 37607

2 studies enrolling now · 12 studies all time

What they study most

Adjunctive Treatment of Major Depressive Disorder, Alzheimer's Disease, Depression, Major Depressive Disorder, Schizophrenia

Studies at this site

• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — Recruiting now
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) — Recruiting now
• A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia — Running, not enrolling
• Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Completed
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® — Stopped early
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed